Lipocine (LPCN) Competitors $4.87 +0.19 (+4.06%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LPCN vs. DERM, ANRO, IMUX, SKYE, MNOV, CNTX, AVTX, PYXS, IPSC, and CLLSShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Journey Medical (DERM), Alto Neuroscience (ANRO), Immunic (IMUX), Skye Bioscience (SKYE), MediciNova (MNOV), Context Therapeutics (CNTX), Avalo Therapeutics (AVTX), Pyxis Oncology (PYXS), Century Therapeutics (IPSC), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Journey Medical Alto Neuroscience Immunic Skye Bioscience MediciNova Context Therapeutics Avalo Therapeutics Pyxis Oncology Century Therapeutics Cellectis Journey Medical (NASDAQ:DERM) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Do insiders & institutionals believe in DERM or LPCN? 7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 13.2% of Journey Medical shares are owned by insiders. Comparatively, 6.1% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend DERM or LPCN? Journey Medical presently has a consensus price target of $9.38, suggesting a potential upside of 100.32%. Lipocine has a consensus price target of $10.00, suggesting a potential upside of 105.34%. Given Lipocine's higher possible upside, analysts plainly believe Lipocine is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DERM or LPCN more profitable? Lipocine has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. Lipocine's return on equity of -19.17% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-31.74% -132.10% -26.90% Lipocine N/A -19.17%-17.60% Which has more risk and volatility, DERM or LPCN? Journey Medical has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Does the MarketBeat Community favor DERM or LPCN? Lipocine received 342 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 69.26% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformJourney MedicalOutperform Votes5100.00% Underperform VotesNo VotesLipocineOutperform Votes34769.26% Underperform Votes15430.74% Does the media refer more to DERM or LPCN? In the previous week, Lipocine had 5 more articles in the media than Journey Medical. MarketBeat recorded 6 mentions for Lipocine and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.93 beat Lipocine's score of 0.23 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lipocine 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, DERM or LPCN? Journey Medical has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$57.77M1.69-$3.85M-$0.94-4.98Lipocine$7.92M3.29-$16.35M-$0.76-6.41 SummaryLipocine beats Journey Medical on 10 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.05M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-6.4110.5990.0517.18Price / Sales3.29195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book1.275.094.784.78Net Income-$16.35M$151.83M$120.31M$225.60M7 Day Performance-2.99%-2.13%-1.92%-1.23%1 Month Performance-2.60%-3.10%11.50%3.36%1 Year Performance66.48%11.54%30.59%16.60% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine1.5291 of 5 stars$4.87+4.1%$10.00+105.3%+66.5%$26.05M$7.92M-6.4110News CoverageDERMJourney Medical2.5422 of 5 stars$5.04-1.0%$9.38+86.0%N/A$105.29M$79.18M-5.4190ANROAlto Neuroscience3.2643 of 5 stars$3.83flat$20.00+422.2%N/A$103.30M$210,000.000.00N/AGap UpIMUXImmunic2.773 of 5 stars$1.15+1.3%$11.80+930.6%-28.6%$103.14MN/A-0.9270Positive NewsSKYESkye Bioscience2.1841 of 5 stars$3.38+0.9%$18.67+452.3%-11.8%$102.54MN/A0.0011News CoveragePositive NewsGap DownMNOVMediciNova2.1626 of 5 stars$2.09-0.5%$9.00+330.6%+46.6%$102.51M$1M-9.9510Analyst ForecastPositive NewsCNTXContext Therapeutics2.9747 of 5 stars$1.35-2.9%$6.80+403.7%-8.1%$101.25MN/A-1.477Positive NewsGap DownAVTXAvalo Therapeutics3.7112 of 5 stars$9.74+5.5%N/A-25.8%$101.24M$820,000.000.0040Analyst ForecastNews CoveragePositive NewsPYXSPyxis Oncology2.1397 of 5 stars$1.67+3.1%$10.00+498.8%+1.2%$99.32MN/A-1.5760Analyst ForecastNews CoveragePositive NewsIPSCCentury Therapeutics1.8159 of 5 stars$1.16-4.9%$11.60+900.0%-52.8%$98.63M$2.68M-0.66170Gap DownHigh Trading VolumeCLLSCellectis3.1716 of 5 stars$1.76-0.2%$7.00+298.6%-51.3%$97.62M$9.19M-1.35290 Related Companies and Tools Related Companies DERM Alternatives ANRO Alternatives IMUX Alternatives SKYE Alternatives MNOV Alternatives CNTX Alternatives AVTX Alternatives PYXS Alternatives IPSC Alternatives CLLS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPCN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
